PTGER4 (prostaglandin E receptor 4) is a prostanoid transmembrane receptor, which has 7 membrane spanning regions. This gene is localized to human chromosome 5p13.1. It is one of the four members of the receptors of prostaglandin E2 (PGE2), and is a G-protein coupled receptor.
Prostaglandin E2 receptor EP4 subtype recombinant protein epitope signature tag (PrEST)
All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.
The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
PTGER4 (prostaglandin E receptor 4) binds to prostaglandin E2 (PGE2), and activates Gs protein, which leads to increase of intracellular cAMP levels and decrease of Ca2+ levels. Studies show that activation of this protein prevents the aggregation of platelets and has an anti-thrombotic effect. The expression of PTGER4 is enhanced by transforming growth factor β (TGF-β), which leads to an increase in PGE2-driven virulence of Theileria annulata-transformed macrophages. The SNP rs7720838 in this gene is associated with increased susceptibility to Crohn′s disease. This gene is up-regulated in lymphocytic colitis, and the expression is related with increased tumor necrosis factor-α (TNF-α) expression. PTGER4 has anti-inflammatory activity, where it inhibits the reorganization of junction and cytoskeletons of endothelial cells, promotes the healing of microvascular endothelial monolayers of lungs, and prevents the adhesion and migration of neutrophils.
Features and Benefits
Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.
Every Prestige Antibody is tested in the following ways:
- IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
- Protein array of 364 human recombinant protein fragments.
Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide
Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.